Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Hackensack Meridian Health Hackensack, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Stamford Hospital/Bennett Cancer Center Stamford, Connecticut, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Lifespan Cancer Institute Providence, Rhode Island, United States
View Trial Details
Active, Not Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748

Conditions
AML/MDS, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +33 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • TriStar Bone Marrow Transplant Nashville, Tennessee, United States
View Trial Details
Active, Not Recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

NCT03410875

Conditions
Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

NCT04155749

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Advanced Cellular Therapeutics Facility, DCAM 0800A Chicago, Illinois, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Froedtert Hospital/Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions